Ignite Creation Date:
2025-12-24 @ 5:42 PM
Ignite Modification Date:
2026-02-01 @ 4:44 PM
Study NCT ID:
NCT04471168
Status:
RECRUITING
Last Update Posted:
2025-04-03
First Post:
2020-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Interest of Auriculotherapy in the Management of Chronic Insomnia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007319', 'term': 'Sleep Initiation and Maintenance Disorders'}], 'ancestors': [{'id': 'D020919', 'term': 'Sleep Disorders, Intrinsic'}, {'id': 'D020920', 'term': 'Dyssomnias'}, {'id': 'D012893', 'term': 'Sleep Wake Disorders'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['PARTICIPANT']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 72}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2020-10-14', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2025-10-14', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-04-01', 'studyFirstSubmitDate': '2020-06-10', 'studyFirstSubmitQcDate': '2020-07-09', 'lastUpdatePostDateStruct': {'date': '2025-04-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-07-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10-14', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of patients with improvement of insomnia after 3 month of treatment (Real Auriculotherapy group compared to Sham Auriculotherapy group)', 'timeFrame': '3 months', 'description': 'Comparison of the evolution of the score of the Insomnia Severity Index (7-item self-report questionnaire assessing the nature, severity, and impact of insomnia).\n\nTotal score categories:\n\n0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)\n\nThe improvement will be defined as a decrease in the score of the questionnaire by 3 points between Day 90 and Day 0.\n\nA comparison of the improvement according to the 2 arms will be made.'}], 'secondaryOutcomes': [{'measure': 'Evolution of sleep quality and sleep disorders', 'timeFrame': '3 months', 'description': 'Specific questionnaire Pittsburgh Sleep Quality Index (PSQI)at inclusion and at 3 months (1 month post-treatment).\n\nSeven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21).\n\nHigher scores indicate worse sleep quality.'}, {'measure': 'Evolution of drug consumption linked to chronic insomnia', 'timeFrame': '3 months', 'description': 'Drugs used to control chronic insomnia will be collected from the inclusion to 3 months (1 month post-treatment)'}, {'measure': 'Evolution and Anxiety and depression', 'timeFrame': '3 months', 'description': 'Hospital Anxiety and Depression questionnaire will be used at inclusion and at 3 months post-treatment.\n\nThere are seven questions related to anxiety (total A) and seven others related to the depressive dimension (total D), allowing thus obtaining two scores (maximum score of each score = 21).\n\nHigher score indicates a certain symptomatology :\n\n* 7 or less: absence of symptoms\n* 8 to 10: doubtful symptomatology\n* 11 and more: certain symptomatology.'}, {'measure': 'Evolution of quality of life', 'timeFrame': '3 months', 'description': "EuroQoL five Dimension questionnaire at inclusion and at 3 months post-treatment. This questionnaire is designed for the patient to judge the impact of his state of health on his quality of life according to 5 dimensions (mobility, personal autonomy, daily activities, pain / discomfort and anxiety / depression). Each item has 3 response levels (1, 2 and 3) and the combination of the five digits will represent the patient's state of health. It is supplemented by a quality of life thermometer graduated from 0 (worst quality of life) to 100 (best quality of life)."}, {'measure': 'Overall patient impression', 'timeFrame': '3 months', 'description': "Patient Global Impression of Change questionnaire (PGIC) used at the end of the follow-up.\n\nThis scale evaluates all aspects of patients' health and assesses if there has been an improvement or decline in clinical status with a seven-point single-item scale ranging from 'very much worse' to 'very much improved'"}, {'measure': 'Willingness of the patient to continue treatment', 'timeFrame': '3 months', 'description': 'Patient will be asked at the end of the study if they want to pursue the treatment'}, {'measure': 'Tolerance of cryotherapy auriculotherapy treatment.', 'timeFrame': '3 months', 'description': 'The presence or absence of adverse events attributed to the treatment of auriculotherapy by the patient.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Cryo auriculotherapy'], 'conditions': ['Chronic Insomnia']}, 'descriptionModule': {'briefSummary': 'The aim of the study is to show that auriculotherapy is effective in the treatment of chronic insomnia.', 'detailedDescription': 'Chronic insomnia affects a significant proportion of the French population with an estimated prevalence between 15% and 20%.\n\nThis disease is mainly managed by general practitioners for whom benzodiazepines and Z-drugs (zopiclone, zolpidem) represent the first-line treatment. The french health authorities recommend limiting the consumption of these molecules to 2 to 4 weeks taking into account their possible undesirable effects (eg memory impairment, in the elderly, road accident) as well as the risk of tolerance and addiction. However, it appears that a majority of the patients concerned become chronic consumers.\n\nThe investigators propose to assess cryo-auriculotherapy in the treatment of chronic insomnia.\n\nThe population studied will consist of patients with chronic insomnia, whose diagnosis has been made according to the definition in the diagnostic and statistical manual of mental disorders (DSM-5), and followed up in an outpatient clinic at Foch Hospital or in one of the participating centers.\n\nHalf of the patients will be treated with cryo-auriculotherapy (use of a device with nitrous oxide) and compared with control patients who will have the same treatment visits involving a sham device (device without nitrous oxide).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '64 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Suffering from chronic insomnia as defined in the diagnostic and statistical manual of mental disorders (DSM-5)\n* Score ≥ 15 on the Insomnia Severity Index (ISI) questionnaire;\n* Covered by a national healthcare insurance\n* Consent form signed\n\nExclusion Criteria:\n\n* Pregnant woman or pregnancy planned for the duration of the study;\n* Regular night work or shift work / reversal of sleep patterns;\n* Trans meridian travel during the previous month or planned during the study period;\n* Unstable or untreated psychiatric disorder including severe depression, severe addiction, unbalanced bipolar disorder;\n* Taking insomnia-inducing drugs (eg Corticoids);\n* Hypnotic treatment or antidepressant treatment with hypnotic aim introduced since less than 4 weeks or with change dating back less than 4 weeks;\n* Presence of organic comorbidities which may be responsible for sleep disorders (SAS and restless legs syndrome): (STOP-BANG) score ≥ 5;\n* History of central neurological disorders or progressive brain injury;\n* Contraindication to the use of auriculotherapy (lesion or infection of the pinna) by cryotherapy (skin scarring disorder, risk of hypo or hyperpigmentation);\n* Treatment by auriculotherapy or acupuncture in this indication in the previous 12 months;\n* Previous treatment with cryo-auriculotherapy\n* Having started in the month preceding the first auriculotherapy session, any new treatment likely to interfere with the study: specific drug treatment (antidepressant, morphine or anticonvulsant) or complementary therapy (psychological care, physiotherapy, balneotherapy, etc.).\n* Difficulty complying with the treatment, questionnaire or study protocol.\n* Be deprived of liberty or under guardianship.'}, 'identificationModule': {'nctId': 'NCT04471168', 'acronym': 'AURICULO-DODO', 'briefTitle': 'Interest of Auriculotherapy in the Management of Chronic Insomnia', 'organization': {'class': 'OTHER', 'fullName': 'Hopital Foch'}, 'officialTitle': 'Interest of Auriculotherapy in the Management of Chronic Insomnia', 'orgStudyIdInfo': {'id': '2018_0107'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cryo-Auriculotherapy', 'description': 'Patients benefit from 3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.', 'interventionNames': ['Device: Cryo-Auriculotherapy']}, {'type': 'SHAM_COMPARATOR', 'label': 'Control group', 'description': 'Patients benefit from 3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.', 'interventionNames': ['Device: Sham comparator']}], 'interventions': [{'name': 'Cryo-Auriculotherapy', 'type': 'DEVICE', 'description': '3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.', 'armGroupLabels': ['Cryo-Auriculotherapy']}, {'name': 'Sham comparator', 'type': 'DEVICE', 'description': '3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.', 'armGroupLabels': ['Control group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '97132', 'city': 'Issy-les-Moulineaux', 'state': 'Hauts de Seine', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Sabrina MA, MD', 'role': 'CONTACT', 'email': 'sabrina.ma@ville-issy.fr'}, {'name': 'Sabrina MA, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Espace Santé Simone Veil', 'geoPoint': {'lat': 48.82104, 'lon': 2.27718}}, {'zip': '78158', 'city': 'Le Chesnay', 'state': 'Yvelines', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': 'Cabinet Médical Nouvelle France', 'geoPoint': {'lat': 48.8222, 'lon': 2.12213}}, {'zip': '78423', 'city': 'Montigny-le-Bretonneux', 'state': 'Yvelines', 'status': 'ACTIVE_NOT_RECRUITING', 'country': 'France', 'facility': "Cabinet de l'Olivier", 'geoPoint': {'lat': 48.76636, 'lon': 2.03405}}, {'zip': '92150', 'city': 'Suresnes', 'status': 'RECRUITING', 'country': 'France', 'contacts': [{'name': 'Mireille Michel-Cherqui, MD', 'role': 'CONTACT', 'email': 'm.michel-cherqui@hopital-foch.org', 'phone': '+33(0)146252985'}], 'facility': 'Hopital Foch', 'geoPoint': {'lat': 48.87143, 'lon': 2.22929}}], 'centralContacts': [{'name': 'Mireille Michel-Cherqui, MD', 'role': 'CONTACT', 'email': 'm.michel-cherqui@hopital-foch.org', 'phone': '+33(0)146252985'}], 'overallOfficials': [{'name': 'Mireille Michel-Cherqui, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hopital Foch'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hopital Foch', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}